Use of bone morphogenetic protein in lumbar fusion may yield high risk profile

335202

February 23, 2021

1 min read

Source/Disclosures

Published by:

Source:

Syed K, et al. Paper 14. Presented at: Lumbar Spine Research Society Annual Meeting; Nov. 12-15, 2020 (virtual meeting).

Disclosures: Parola reports no relevant financial disclosures.

ADD TOPIC TO EMAIL ALERTS

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

ADDED TO EMAIL ALERTS

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Use of bone morphogenetic protein in single-level lumbar fusion may have a higher risk profile than previously reported with non-significant benefits, according to results.

Rown Parola, MS, and colleagues categorized 362,530 Medicare patients who underwent single-level lumbar fusion between 2004 and 2014 into groups based on whether they received bone morphogenetic protein (BMP).

“The demographics and comorbidities were also identified by ICD-9 diagnosis code, and then we underwent propensity matching, trying to match our cohorts along the basis of age, Elixhauser comorbidity index, sex, region, treatment year, smoking status, osteoporotic status and nutritional status,” Parola said in his presentation at the Lumbar Spine Research Society Annual Meeting…

Want to know more click here go to source.

From -
Close
Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages

Site Language


By continuing to use the site, you agree to the use of cookies. more information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close